Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
RICHMOND, Calif., Feb. 28, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the company plans to participate in the 29th Annual Roth Conference in Orange County, CA.
Ekso Bionics’ management is scheduled to present Tuesday, March 14, 2017 at 5:00 p.m. PDT. Interested parties can access the live audio webcast by navigating to the “IR Calendar” area of the “News/Events” section at www.ir.eksobionics.com. An archived presentation will also be available on the website.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 [email protected] Investor Contact: Debbie Kaster 415-937-5403 [email protected]
